Pharmazell Gmbh

Evonik Degussa Gmbh

Dirk Weuster-Botz

Arno Aigner

Michael Braun

Boqiao Sun

Werner Hummel

Daniel Bakonyi

Sven Bresch

Christina Kantzow

Thomas Haas

Rolf Schmid

Liv Reinecke

Yvonne Schiemann

Luo Sha Liu

Christian Quirin

Harald Krispin

Monika Johanna Krispin

Wilhelm Krispin

Luo Liu

In various aspects and embodiments, the invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a 7β-hydroxysteroid dehydrogenase (7β-HSDH) mutant that catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has, compared to the wildtype 7β-HSDH of SEQ ID NO:2, a decreased substrate inhibition and/or an altered cofactor usage, and the mutant has, in comparison with the wildtype 7β-HSDH of SEQ ID NO:2, 1 to 15 amino acid additions, substitutions, deletions and/or inversions in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2.

7β-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid

The invention relates to novel 7&#xdf;-hydroxysteroid dehydrogenase mutants, to the sequences which encode these enzyme mutants, to processes for the preparation of the enzyme mutants and to their use in enzymatic reactions of cholic acid compounds, in particular in the preparation of ursodeoxycholic acid (UDCS). The invention also relates to novel processes for the synthesis of UDCS using the enzyme mutants; and to the preparation of UDCS using recombinant, multiply-modified microorganisms.

7Beta-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid

The invention relates to novel biocatalytic processes comprising the whole cell reduction of dehydrocholic acid (DHCA) compounds, novel 7&#x3b2;-hydroxy steroid dehydrogenase mutants, the sequences coding for these enzyme mutants, methods for producing the enzyme mutants and use thereof in enzymatic conversions of cholic acid compounds, and in particular in the production of ursodesoxycholic acid (UDCA); also a subject of the invention are novel methods for the synthesis of UDCA using the enzyme mutants; and in particular a further improved method for producing UDCA using recombinant whole cell biocatalysts.

Method for biocatalytic whole cell reduction of dehydrocholic acid compounds, and 7-&#x3b2;-hydroxysteroid dehydrogenase mutants

The present invention relates to a method for producing C4 bodies, preferably butyric acid and/or butanol, comprising the steps contacting an aqueous medium comprising an acetogenic bacterial cell in an aqueous medium with syngas and incubating the mixture obtained in step a) at a temperature between 0 and 100&#xb0; C. for at least 30 minutes, wherein the aqueous medium comprises, in step b), ethanol and/or acetate at a total combined concentration is at least 0.1 gL.

Biotechnological method for producing butanol and butyric acid

The invention relates to 12 &#x3b1;-hydroxysteroid dehydrogenases, nucleic acid sequences coding for the same, expression cassettes and vectors, recombinant microorganisms containing the corresponding coding nucleic acid sequences, a method for producing said 12 &#x3b1;-hydroxysteroid dehydrogenases, a method for enzymatic oxidation of 12 &#x3b1;-hydroxysteroids using said enzyme, a method for enzymatic reduction of 12-ketosteroids using said enzyme, a method for qualitative or quantitative determination of 12-ketosteroids and/or 12&#x3b1;-hydroxysteroids using said 12&#x3b1;-hydroxysteroid dehydrogenases and a method for production of ursodesoxycholic acid, comprising the enzyme-catalyzed cholic acid oxidation using said 12 &#x3b1;-hydroxysteroid dehydrogenases.

7 &#x3b1;-hydroxysteroid dehydrogenase knockout mutants and use therefor

Growing community of inventors

Munich, Germany

Dirk Weuster-Botz